31 May 2023
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Results of Annual General Meeting
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company’s Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 28 April 2023.
The poll results were as follows.
|
Resolution |
Title |
For |
For % |
Against |
Against % |
Total Votes |
% Issued Capital |
|
1 |
FINANCIAL STATEMENTS |
135,930,178 |
100.00% |
2,600 |
0.00% |
135,932,778 |
62.61% |
|
2 |
REMUNERATION REPORT |
134,448,331 |
98.78% |
1,660,110 |
1.22% |
136,108,441 |
62.69% |
|
3 |
AUDITOR REMUNERATION |
129,945,308 |
95.88% |
5,579,727 |
4.12% |
135,525,035 |
62.42% |
|
4 |
RE-ELECT P ALLEN |
121,131,315 |
88.99% |
14,989,308 |
11.01% |
136,120,623 |
62.70% |
|
5 |
RE-ELECT G COOK |
123,309,347 |
90.59% |
12,804,964 |
9.41% |
136,114,311 |
62.69% |
|
6 |
RE-ELECT D LE FORT |
123,977,756 |
91.08% |
12,136,555 |
8.92% |
136,114,311 |
62.69% |
|
7 |
ELECT L SHANAHAN |
136,068,717 |
99.97% |
45,594 |
0.03% |
136,114,311 |
62.69% |
|
8 |
RE-ELECT C MEREDITH |
131,687,725 |
96.74% |
4,434,124 |
3.26% |
136,121,849 |
62.70% |
|
9 |
RE-ELECT E JOHNSON |
133,113,126 |
97.80% |
3,001,185 |
2.20% |
136,114,311 |
62.69% |
|
10 |
FINAL DIVIDEND |
136,127,581 |
100.00% |
278 |
0.00% |
136,127,859 |
62.70% |
|
11 |
ALLOT SHARES* |
135,448,934 |
99.52% |
654,222 |
0.48% |
136,103,156 |
62.69% |
|
12 |
PRE-EMPTION RIGHTS* |
129,949,465 |
95.47% |
6,165,524 |
4.53% |
136,114,989 |
62.69% |
|
13 |
PURCHASE SHARES* |
135,042,435 |
99.95% |
63,012 |
0.05% |
135,105,447 |
62.23% |
* Special Resolution
|
Notes: 1. Votes “For” and “Against” are expressed as a percentage of votes received. 2. A “Vote withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution. 3. Total number of shares in issue at close of business on 26 May = 217,109,419 shares. 62.63% of the voting capital was instructed. |
– Ends –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Matthew Neal / Lucy Featherstone |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Gary Clarence / David Anderson |
|
|
|
|
|
HSBC Bank PLC (Broker) |
Tel: 44 (0) 20 7991 8888 |
|
Sam McLennan / Joe Weaving / Stephanie Cornish |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Austria, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGFLFIVEVILVIV